What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Mirikizumab shows comparable efficacy to existing treatments like vedolizumab and ustekinumab, meeting non-inferiority but lacking direct head-to-head trial data. The evidence indicates it is more effective than placebo, but the absence of direct comparisons limits the strength of the claim.
Does the economic case hold at the expected price? — Cost effectiveness
Mirikizumab is suggested to be cost-effective as it is priced similarly or lower than vedolizumab and ustekinumab, which supports its recommendation. The cost comparison methods used by NICE indicate it meets the necessary criteria for cost-effectiveness.
Is there quality-of-life evidence payers weigh? — Quality of life
The document does not provide specific data on HRQoL improvements associated with mirikizumab. While it is implied that the treatment may improve quality of life, the lack of validated tools or significant data means no demonstrated benefit can be confirmed.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of mirikizumab appears acceptable, with no significant adverse effects reported in the document. However, the absence of detailed safety data compared to existing treatments limits the robustness of this assessment.
Was the drug compared against what payers expect? — Comparator Selection
The document indicates that mirikizumab has not been directly compared to vedolizumab or ustekinumab, which are key comparators. The reliance on indirect comparisons raises concerns about the validity of the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The patient population for mirikizumab is well-defined, targeting adults with moderately to severely active ulcerative colitis who have not responded to or cannot tolerate other treatments. This specificity supports its relevance to the intended population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Mirikizumab can be integrated into existing treatment pathways for ulcerative colitis with minimal disruption, as it is positioned as an alternative to existing therapies. The recommendations indicate that it fits well within current clinical practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The document suggests that mirikizumab has a manageable budget impact, particularly due to its commercial arrangement that provides a discount. This indicates a favorable economic profile for the Healthcare.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While there is clinical trial evidence supporting the efficacy of mirikizumab, the lack of direct comparisons and reliance on indirect evidence introduces some uncertainty regarding the robustness of the findings.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
The document indicates a favorable context for mirikizumab, with manageable uncertainties regarding its integration and effectiveness. The treatment addresses an unmet need in patients who have not responded to other therapies.
